Researchers from the University of Cambridge have made a significant breakthrough by eliminating the risks associated with activating the immune system via the STING pathway, opening up new possibilities for safe and effective cancer treatment.

The Immune System vs. Cancer: Modern Approaches

Harnessing innate immunity to treat cancer is considered one of the most promising strategies in contemporary medicine. For example, this summer, scientists presented evidence supporting the concept of a universal cancer vaccine that trains the immune system to recognize and destroy any cancer cells in the body.

The STING Pathway: How the Mechanism Works

One of the key immunological pathways being studied for cancer therapy is the STING pathway (stimulator of interferon genes). It acts as a signaling system: when foreign DNA is detected in the cytoplasm, the cell releases the cGAS sensor protein, which then activates the STING protein on the cell membrane. This triggers a cascade of reactions, recruiting other elements of the immune system to attack the threat.

Challenges with Existing Drugs

To activate this pathway in cancer therapy, STING agonist drugs are used. However, their main drawback is that they do not always act strictly within the tumor area, which can cause dangerous inflammatory reactions in healthy tissues and lead to serious side effects.

A New Solution: A Two-Component Delivery System

To improve the effectiveness and safety of therapy, Cambridge scientists have developed an innovative two-component drug delivery system. In this system, one part of the medication is chemically "locked" and remains inactive until it encounters specific conditions. In this case, the STING agonist called MSA2 is released only upon contact with the enzyme β-glucuronidase, which is produced by tumors and is rarely found in healthy tissues. After activation, the drug mixes with the second component inside the tumor, triggering the STING pathway and mobilizing the immune system to destroy cancer cells.

Lead researcher Gonçalo Bernardes compared this approach to sending two safe packages that only open and combine when they meet the unique chemistry of the tumor. As a result, the active immunomodulatory drug appears exclusively where it is needed.

Trial Results and Future Prospects

The two-component drug was tested on mice and genetically modified zebrafish capable of producing β-glucuronidase. Experiments showed that the drug is activated almost exclusively in tumor tissues, sparing healthy organs.

Beyond cancer treatment, the researchers believe their discovery could help create highly precise drug delivery systems for various medical applications. As noted by first author Nai-Shu Hsu, this approach is promising not only for oncology but also as a new way to develop safer and more targeted medications.

The results of the study have been published in the journal Nature Chemistry.